VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2011

ABSTRACT

Background: - New vaccines against avian influenza, also known as "bird flu," are being developed and require testing to determine if they are safe and effective and whether they have any side effects. Researchers are interested in testing two experimental avian influenza vaccines to see whether they are safe, if there are any side effects from the vaccines, and how the body's immune response differs in response to different vaccination schedules. One vaccine is an inactivated vaccine (made with killed or weakened influenza) and one is a DNA vaccine that allows the body to use vaccine to make an immune system response to a specific part of an avian influenza protein. Objectives: - To determine the safety and potential side effects of two experimental vaccines against avian influenza. - To evaluate whether the time between the two experimental vaccine injections affects the immune response to the vaccine. Eligibility: - Healthy individuals between 18 and 60 years of age. Design: - Participants will be randomly divided (by chance) into six groups to receive two injections of vaccine at different intervals. One group will receive only the inactivated vaccine, while the other groups will receive the DNA vaccine followed by the inactivated vaccine at different intervals (e.g., 4 weeks, 8 weeks, 12 weeks, 16 weeks or 24 weeks later). - Participants will remain at the clinical center for at least 30 minutes after each vaccination. A few days after each injection, participants will contact staff by telephone or have a clinic visit. Participants will also be asked to complete a diary card at home for 5 days to keep track of temperature changes, injection site skin changes, and other effects. - Four weeks after the first injection, participants will return for a clinic visit and to provide blood samples for testing. - Two weeks after the second injection, participants will return for a clinic visit and provide blood samples (collected through apheresis) to provide information on immune response to the vaccine. Detailed Description An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals with Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine, VRC-AVIDNA036-00-VP (VRC, NIAID) Study Design: This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and immunogenicity of prime-boost vaccination regimens against the influenza virus hemagglutinin H5. One group will receive A/Indonesia/05/2005 (inactivated H5N1) vaccine as both prime and boost, and the other groups will receive the VRC-AVIDNA036-00-VP (DNA) vaccine as prime with inactivated H5N1 boost but with various boost intervals. The VRC 310 study will provide data from different prime-boost schedules to identify whether homologous or heterologous schedules result in a better antibody response as well as which interval of time between vaccinations is associated with the best immune response. The hypothesis is that all of the study regimens will be safe for human administration and will elicit antibody and T cell responses against the H5 protein. The primary objectives are to evaluate the safety and tolerability of the investigational vaccine regimens, at a dose of 4 mg for the DNA vaccine and 90 microg for the inactivated H5N1, in healthy adults. Secondary and exploratory objectives are related to the immunogenicity of the study vaccine regimens and identification of an interval between prime and boost that has the highest frequency of strong immune responses. Product Description: The inactivated H5N1 vaccine is monovalent subunit virion vaccine, A/Indonesia/05/2005 clade 2, manufactured by Sanofi Pasteur, Inc (Swiftwater, PA). Vaccine vials will be supplied at 90 microg/0.5mL. The VRC-AVIDNA036-00-VP vaccine was developed and manufactured by VRC, NIAID and is composed of a single closed-circular DNA plasmid that encodes the H5 protein with a CMV/R promoter. Vaccine vials will be supplied at 4 mg/mL. Each vaccination will be administered intramuscularly (IM) in the deltoid muscle using needle and syringe for the H5N1 vaccine and the Biojector 2000 Needle-Free Injection Management System (Biojector) for the DNA vaccine. Subjects: A total of 60 healthy adults, ages 18-60 years will be enrolled. Study Plan: Subjects will be simultaneously randomized equally into one of 6 groups. Subjects and clinicians will be blinded to group assignment until Day 0 following completion of the enrollment. At the point of enrollment the randomly assigned regimen will become known to subjects and clinicians. Subjects will receive two injections on the schedule shown in the schema. The protocol requires 5 or 6 clinic visits, depending upon the group, and telephone follow-up contact after the first study injection and 24 weeks after the second study injection. Additional optional visits may be conducted at study weeks 48 and 72 to collect blood for evaluation of immune response durability. Study Duration: Each participant will complete clinical follow up through 24 weeks after the second vaccination. Duration of the expected time on study will vary from 28 to 48 weeks depending upon the Group, but may be extended to 72 weeks after enrollment for subjects who agree to complete the optional research blood drawas. More... »

URL

https://clinicaltrials.gov/show/NCT01086657

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background: - New vaccines against avian influenza, also known as \"bird flu,\" are being developed and require testing to determine if they are safe and effective and whether they have any side effects. Researchers are interested in testing two experimental avian influenza vaccines to see whether they are safe, if there are any side effects from the vaccines, and how the body's immune response differs in response to different vaccination schedules. One vaccine is an inactivated vaccine (made with killed or weakened influenza) and one is a DNA vaccine that allows the body to use vaccine to make an immune system response to a specific part of an avian influenza protein. Objectives: - To determine the safety and potential side effects of two experimental vaccines against avian influenza. - To evaluate whether the time between the two experimental vaccine injections affects the immune response to the vaccine. Eligibility: - Healthy individuals between 18 and 60 years of age. Design: - Participants will be randomly divided (by chance) into six groups to receive two injections of vaccine at different intervals. One group will receive only the inactivated vaccine, while the other groups will receive the DNA vaccine followed by the inactivated vaccine at different intervals (e.g., 4 weeks, 8 weeks, 12 weeks, 16 weeks or 24 weeks later). - Participants will remain at the clinical center for at least 30 minutes after each vaccination. A few days after each injection, participants will contact staff by telephone or have a clinic visit. Participants will also be asked to complete a diary card at home for 5 days to keep track of temperature changes, injection site skin changes, and other effects. - Four weeks after the first injection, participants will return for a clinic visit and to provide blood samples for testing. - Two weeks after the second injection, participants will return for a clinic visit and provide blood samples (collected through apheresis) to provide information on immune response to the vaccine.\n\nDetailed Description\nAn Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals with Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine, VRC-AVIDNA036-00-VP (VRC, NIAID) Study Design: This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and immunogenicity of prime-boost vaccination regimens against the influenza virus hemagglutinin H5. One group will receive A/Indonesia/05/2005 (inactivated H5N1) vaccine as both prime and boost, and the other groups will receive the VRC-AVIDNA036-00-VP (DNA) vaccine as prime with inactivated H5N1 boost but with various boost intervals. The VRC 310 study will provide data from different prime-boost schedules to identify whether homologous or heterologous schedules result in a better antibody response as well as which interval of time between vaccinations is associated with the best immune response. The hypothesis is that all of the study regimens will be safe for human administration and will elicit antibody and T cell responses against the H5 protein. The primary objectives are to evaluate the safety and tolerability of the investigational vaccine regimens, at a dose of 4 mg for the DNA vaccine and 90 microg for the inactivated H5N1, in healthy adults. Secondary and exploratory objectives are related to the immunogenicity of the study vaccine regimens and identification of an interval between prime and boost that has the highest frequency of strong immune responses. Product Description: The inactivated H5N1 vaccine is monovalent subunit virion vaccine, A/Indonesia/05/2005 clade 2, manufactured by Sanofi Pasteur, Inc (Swiftwater, PA). Vaccine vials will be supplied at 90 microg/0.5mL. The VRC-AVIDNA036-00-VP vaccine was developed and manufactured by VRC, NIAID and is composed of a single closed-circular DNA plasmid that encodes the H5 protein with a CMV/R promoter. Vaccine vials will be supplied at 4 mg/mL. Each vaccination will be administered intramuscularly (IM) in the deltoid muscle using needle and syringe for the H5N1 vaccine and the Biojector 2000 Needle-Free Injection Management System (Biojector) for the DNA vaccine. Subjects: A total of 60 healthy adults, ages 18-60 years will be enrolled. Study Plan: Subjects will be simultaneously randomized equally into one of 6 groups. Subjects and clinicians will be blinded to group assignment until Day 0 following completion of the enrollment. At the point of enrollment the randomly assigned regimen will become known to subjects and clinicians. Subjects will receive two injections on the schedule shown in the schema. The protocol requires 5 or 6 clinic visits, depending upon the group, and telephone follow-up contact after the first study injection and 24 weeks after the second study injection. Additional optional visits may be conducted at study weeks 48 and 72 to collect blood for evaluation of immune response durability. Study Duration: Each participant will complete clinical follow up through 24 weeks after the second vaccination. Duration of the expected time on study will vary from 28 to 48 weeks depending upon the Group, but may be extended to 72 weeks after enrollment for subjects who agree to complete the optional research blood drawas.", 
    "endDate": "2011-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01086657", 
    "keywords": [
      "label", 
      "PHS", 
      "healthy adult", 
      "virion", 
      "H5N1", 
      "vaccine", 
      "Inc", 
      "DNA vaccine", 
      "Influenza in Bird", 
      "bird flu", 
      "side effect", 
      "influenza vaccine", 
      "body", 
      "immune response", 
      "vaccination", 
      "inactivated vaccine", 
      "immune system response", 
      "specific part", 
      "protein", 
      "safety", 
      "potential side effect", 
      "experimental vaccine", 
      "eligibility", 
      "healthy individual", 
      "age", 
      "injection", 
      "different interval", 
      "clinical center", 
      "staff", 
      "telephone", 
      "Ambulatory Care", 
      "diary", 
      "home", 
      "Track and Field", 
      "temperature change", 
      "injection site", 
      "blood sample", 
      "Blood Component Removal", 
      "immunogenicity", 
      "interval", 
      "recombinant DNA", 
      "VRC", 
      "National Institute of Allergy and Infectious Disease", 
      "study design", 
      "open-label study", 
      "tolerability", 
      "vaccination regimen", 
      "hemagglutinin", 
      "DNA", 
      "boost", 
      "antibody", 
      "regimen", 
      "human administration", 
      "T cell response", 
      "primary objective", 
      "investigational vaccine", 
      "dose", 
      "exploratory", 
      "vaccine regimen", 
      "high frequency", 
      "strong immune response", 
      "product", 
      "subunit", 
      "clade", 
      "PA", 
      "circular DNA", 
      "promoter", 
      "IM", 
      "muscle", 
      "needle", 
      "syrinx", 
      "management system", 
      "study plan", 
      "clinician", 
      "group assignment", 
      "completion", 
      "enrollment", 
      "Appointment and Schedule", 
      "schema", 
      "protocol", 
      "follow-up", 
      "first study", 
      "second study", 
      "visit", 
      "blood", 
      "Evaluation Study as Topic", 
      "study duration", 
      "duration", 
      "expected time", 
      "Research"
    ], 
    "name": "VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01086657"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00008.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419681.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2010-02-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1093/infdis/jit180", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006900820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009672270", 
          "https://doi.org/10.1038/nature04230"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.immuni.2005.12.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014439474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/infdis/jit178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015328313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(11)70240-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028720731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3201/eid1201.051147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033441828"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01086657"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01086657'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01086657'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01086657'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01086657'


 

This table displays all metadata directly associated to this object as RDF triples.

133 TRIPLES      16 PREDICATES      113 URIs      99 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01086657 schema:about anzsrc-for:3053
2 anzsrc-for:3103
3 schema:description Background: - New vaccines against avian influenza, also known as "bird flu," are being developed and require testing to determine if they are safe and effective and whether they have any side effects. Researchers are interested in testing two experimental avian influenza vaccines to see whether they are safe, if there are any side effects from the vaccines, and how the body's immune response differs in response to different vaccination schedules. One vaccine is an inactivated vaccine (made with killed or weakened influenza) and one is a DNA vaccine that allows the body to use vaccine to make an immune system response to a specific part of an avian influenza protein. Objectives: - To determine the safety and potential side effects of two experimental vaccines against avian influenza. - To evaluate whether the time between the two experimental vaccine injections affects the immune response to the vaccine. Eligibility: - Healthy individuals between 18 and 60 years of age. Design: - Participants will be randomly divided (by chance) into six groups to receive two injections of vaccine at different intervals. One group will receive only the inactivated vaccine, while the other groups will receive the DNA vaccine followed by the inactivated vaccine at different intervals (e.g., 4 weeks, 8 weeks, 12 weeks, 16 weeks or 24 weeks later). - Participants will remain at the clinical center for at least 30 minutes after each vaccination. A few days after each injection, participants will contact staff by telephone or have a clinic visit. Participants will also be asked to complete a diary card at home for 5 days to keep track of temperature changes, injection site skin changes, and other effects. - Four weeks after the first injection, participants will return for a clinic visit and to provide blood samples for testing. - Two weeks after the second injection, participants will return for a clinic visit and provide blood samples (collected through apheresis) to provide information on immune response to the vaccine. Detailed Description An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals with Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine, VRC-AVIDNA036-00-VP (VRC, NIAID) Study Design: This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and immunogenicity of prime-boost vaccination regimens against the influenza virus hemagglutinin H5. One group will receive A/Indonesia/05/2005 (inactivated H5N1) vaccine as both prime and boost, and the other groups will receive the VRC-AVIDNA036-00-VP (DNA) vaccine as prime with inactivated H5N1 boost but with various boost intervals. The VRC 310 study will provide data from different prime-boost schedules to identify whether homologous or heterologous schedules result in a better antibody response as well as which interval of time between vaccinations is associated with the best immune response. The hypothesis is that all of the study regimens will be safe for human administration and will elicit antibody and T cell responses against the H5 protein. The primary objectives are to evaluate the safety and tolerability of the investigational vaccine regimens, at a dose of 4 mg for the DNA vaccine and 90 microg for the inactivated H5N1, in healthy adults. Secondary and exploratory objectives are related to the immunogenicity of the study vaccine regimens and identification of an interval between prime and boost that has the highest frequency of strong immune responses. Product Description: The inactivated H5N1 vaccine is monovalent subunit virion vaccine, A/Indonesia/05/2005 clade 2, manufactured by Sanofi Pasteur, Inc (Swiftwater, PA). Vaccine vials will be supplied at 90 microg/0.5mL. The VRC-AVIDNA036-00-VP vaccine was developed and manufactured by VRC, NIAID and is composed of a single closed-circular DNA plasmid that encodes the H5 protein with a CMV/R promoter. Vaccine vials will be supplied at 4 mg/mL. Each vaccination will be administered intramuscularly (IM) in the deltoid muscle using needle and syringe for the H5N1 vaccine and the Biojector 2000 Needle-Free Injection Management System (Biojector) for the DNA vaccine. Subjects: A total of 60 healthy adults, ages 18-60 years will be enrolled. Study Plan: Subjects will be simultaneously randomized equally into one of 6 groups. Subjects and clinicians will be blinded to group assignment until Day 0 following completion of the enrollment. At the point of enrollment the randomly assigned regimen will become known to subjects and clinicians. Subjects will receive two injections on the schedule shown in the schema. The protocol requires 5 or 6 clinic visits, depending upon the group, and telephone follow-up contact after the first study injection and 24 weeks after the second study injection. Additional optional visits may be conducted at study weeks 48 and 72 to collect blood for evaluation of immune response durability. Study Duration: Each participant will complete clinical follow up through 24 weeks after the second vaccination. Duration of the expected time on study will vary from 28 to 48 weeks depending upon the Group, but may be extended to 72 weeks after enrollment for subjects who agree to complete the optional research blood drawas.
4 schema:endDate 2011-12-01T00:00:00Z
5 schema:keywords Ambulatory Care
6 Appointment and Schedule
7 Blood Component Removal
8 DNA
9 DNA vaccine
10 Evaluation Study as Topic
11 H5N1
12 IM
13 Inc
14 Influenza in Bird
15 National Institute of Allergy and Infectious Disease
16 PA
17 PHS
18 Research
19 T cell response
20 Track and Field
21 VRC
22 age
23 antibody
24 bird flu
25 blood
26 blood sample
27 body
28 boost
29 circular DNA
30 clade
31 clinical center
32 clinician
33 completion
34 diary
35 different interval
36 dose
37 duration
38 eligibility
39 enrollment
40 expected time
41 experimental vaccine
42 exploratory
43 first study
44 follow-up
45 group assignment
46 healthy adult
47 healthy individual
48 hemagglutinin
49 high frequency
50 home
51 human administration
52 immune response
53 immune system response
54 immunogenicity
55 inactivated vaccine
56 influenza vaccine
57 injection
58 injection site
59 interval
60 investigational vaccine
61 label
62 management system
63 muscle
64 needle
65 open-label study
66 potential side effect
67 primary objective
68 product
69 promoter
70 protein
71 protocol
72 recombinant DNA
73 regimen
74 safety
75 schema
76 second study
77 side effect
78 specific part
79 staff
80 strong immune response
81 study design
82 study duration
83 study plan
84 subunit
85 syrinx
86 telephone
87 temperature change
88 tolerability
89 vaccination
90 vaccination regimen
91 vaccine
92 vaccine regimen
93 virion
94 visit
95 schema:name VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine
96 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01086657
97 schema:sdDatePublished 2019-03-07T15:23
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N7ca2636797f44451822d2a72c926ffe6
100 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
101 https://www.grid.ac/institutes/grid.419681.3
102 schema:startDate 2010-02-01T00:00:00Z
103 schema:subjectOf sg:pub.10.1038/nature04230
104 https://doi.org/10.1016/j.immuni.2005.12.005
105 https://doi.org/10.1016/s1473-3099(11)70240-7
106 https://doi.org/10.1093/infdis/jit178
107 https://doi.org/10.1093/infdis/jit180
108 https://doi.org/10.3201/eid1201.051147
109 schema:url https://clinicaltrials.gov/show/NCT01086657
110 sgo:license sg:explorer/license/
111 sgo:sdDataset clinical_trials
112 rdf:type schema:MedicalStudy
113 N7ca2636797f44451822d2a72c926ffe6 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
116 rdf:type schema:DefinedTerm
117 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
118 rdf:type schema:DefinedTerm
119 sg:pub.10.1038/nature04230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009672270
120 https://doi.org/10.1038/nature04230
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1016/j.immuni.2005.12.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014439474
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1016/s1473-3099(11)70240-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028720731
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1093/infdis/jit178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015328313
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1093/infdis/jit180 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006900820
129 rdf:type schema:CreativeWork
130 https://doi.org/10.3201/eid1201.051147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033441828
131 rdf:type schema:CreativeWork
132 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
133 https://www.grid.ac/institutes/grid.419681.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...